PubMed

The effect of comorbid illness and functional status on the expected benefits of intensive glucose control in older patients with type 2 diabetes: a decision analysis.

Huang ES, Zhang Q, Gandra N, Chin MH, Meltzer DO.

Ann Intern Med. 2008 Jul 1;149(1):11-9.PMID: 18591633 [PubMed - indexed for MEDLINE]Related articlesFree article

Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus.

Salas M, Ward A, Caro J.

Clin Ther. 2002 Oct;24(10):1690-705.PMID: 12462297 [PubMed - indexed for MEDLINE]Related articles

Health-related quality of life in the VA Feasibility Study on glycemic control and complications in type 2 diabetes mellitus.

Pitale S, Kernan-Schroeder D, Emanuele N, Sawin C, Sacks J, Abraira C; VACSDM Study Group.

J Diabetes Complications. 2005 Jul-Aug;19(4):207-11.PMID: 15993354 [PubMed - indexed for MEDLINE]Related articles

Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial.

Simon J, Gray A, Clarke P, Wade A, Neil A, Farmer A; Diabetes Glycaemic Education and Monitoring Trial Group.

BMJ. 2008 May 24;336(7654):1177-80. Epub 2008 Apr 17.PMID: 18420663 [PubMed - indexed for MEDLINE]Related articlesFree article

Improving life expectancy and decreasing the incidence of complications associated with type 2 diabetes: a modelling study of HbA1c targets.

Valentine WJ, Palmer AJ, Nicklasson L, Cobden D, Roze S.

Int J Clin Pract. 2006 Sep;60(9):1138-45. Review.PMID: 16939559 [PubMed - indexed for MEDLINE]Related articles

Estimated benefits of glycemic control in microvascular complications in type 2 diabetes.

Vijan S, Hofer TP, Hayward RA.

Ann Intern Med. 1997 Nov 1;127(9):788-95.PMID: 9382399 [PubMed - indexed for MEDLINE]Related articlesFree article

A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.

Tilden DP, Mariz S, O'Bryan-Tear G, Bottomley J, Diamantopoulos A.

Pharmacoeconomics. 2007;25(1):39-54. Erratum in: Pharmacoeconomics. 2007;25(3):237. PMID: 17192117 [PubMed - indexed for MEDLINE]Related articles

Deleterious effects of increased body weight associated with intensive insulin therapy for type 1 diabetes: increased blood pressure and worsened lipid profile partially negate improvements in life expectancy.

Palmer AJ, Roze S, Valentine WJ, Minshall ME, Lammert M, Nicklasson L, Spinas GA.

Curr Med Res Opin. 2004 Aug;20 Suppl 1:S67-73.PMID: 15324518 [PubMed - indexed for MEDLINE]Related articles

Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.

Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, Emanuele NV, Levin SR, Henderson W, Lee HS.

Diabetes Care. 1995 Aug;18(8):1113-23.PMID: 7587846 [PubMed - indexed for MEDLINE]Related articles

Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group.

[No authors listed]

Diabetes Care. 1999 Jul;22(7):1125-36.PMID: 10388978 [PubMed - indexed for MEDLINE]Related articlesFree article

Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization.

Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S.

JAMA. 1997 Nov 26;278(20):1663-9. Erratum in: JAMA 1999 Jun 2;281(21):1989. PMID: 9388085 [PubMed - indexed for MEDLINE]Related articles

Validity of random blood glucose as a predictor of the quality of glycaemic control by glycated haemoglobin in out-patient diabetic patients at Kenyatta National Hospital.

Otieno FC, Ng'ang'a L, Kariuki M.

East Afr Med J. 2002 Sep;79(9):491-5.PMID: 12625691 [PubMed - indexed for MEDLINE]Related articles

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

[No authors listed]

Lancet. 1998 Sep 12;352(9131):837-53. Erratum in: Lancet 1999 Aug 14;354(9178):602. PMID: 9742976 [PubMed - indexed for MEDLINE]Related articles

The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes.

Huang ES, Shook M, Jin L, Chin MH, Meltzer DO.

Diabetes Care. 2006 Feb;29(2):259-64.PMID: 16443870 [PubMed - indexed for MEDLINE]Related articlesFree article

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.

Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group.

Ann Intern Med. 2005 Oct 18;143(8):559-69.PMID: 16230722 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus.

Vijan S, Hofer TP, Hayward RA.

JAMA. 2000 Feb 16;283(7):889-96.PMID: 10685713 [PubMed - indexed for MEDLINE]Related articlesFree article

Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.

Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, McKendrick J, Tucker DM, Foos V, Palmer AJ.

Curr Med Res Opin. 2007 Mar;23(3):609-22.PMID: 17355742 [PubMed - indexed for MEDLINE]Related articles

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

[No authors listed]

Lancet. 1998 Sep 12;352(9131):854-65. Erratum in: Lancet 1998 Nov 7;352(9139):1558. PMID: 9742977 [PubMed - indexed for MEDLINE]Related articles

Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada.

Grima DT, Thompson MF, Sauriol L.

Pharmacoeconomics. 2007;25(3):253-66.PMID: 17335310 [PubMed - indexed for MEDLINE]Related articles

The relationship between physicians' self-reported target fasting blood glucose levels and metabolic control in type 2 diabetes. The QuED Study Group--quality of care and outcomes in type 2 diabetes.

Belfiglio M, De Berardis G, Franciosi M, Cavaliere D, Di Nardo B, Greenfield S, Kaplan SH, Pellegrini F, Sacco M, Tognoni G, Valentini M, Nicolucci A, Caimi V, Capani F, Corsi A, Della Vedova R, Massi Benedetti M, Nicolucci A, Taboga C, Tombesi M, Vespasiani G; QuED Study Group--quality of care and outcomes in type 2 diabetes.

Diabetes Care. 2001 Mar;24(3):423-9.PMID: 11289462 [PubMed - indexed for MEDLINE]Related articlesFree article